Início
Explorar
nav.journalClub
Tendências
Mais
synapse
⌘+K
Idioma
Português
Português
CCDC137 affects sorafenib resistance in hepatocellular carcinoma cells by activating the AKT/mTOR signaling pathway | Synapse
March 3, 2026
CCDC137 affects sorafenib resistance in hepatocellular carcinoma cells by activating the AKT/mTOR signaling pathway
HT
Hanchuan Tao
YW
Yu Fei Wang
University of North Carolina at Chapel Hill
FW
fang Wang
Shihezi University
See all
Key Points
Sorafenib resistance is influenced by the activation of the AKT/mTOR signaling pathway.
CCDC137 plays a key role in modulating liver cancer cell responses to sorafenib treatment.
Analysis of the mechanisms of resistance provides insights into potential treatments for hepatocellular carcinoma.
Finding ways to overcome this resistance could significantly enhance treatment outcomes for patients with liver cancer.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Tao et al. (Tue,) studied this question.
synapsesocial.com/papers/69a7607cc6e9836116a2d456
https://doi.org/https://doi.org/10.1007/s12094-026-04244-5